Corporate Boards

The Scientist, Jan. 10, 1994, page 21): Sheldon Krimsky appears to take the view that if a scientist serves on a board, he or she is guilty until proved innocent. What is the scientist guilty of? The litany includes: (1) not being interested in seeking the truth, as academic purists are, and (2) having a clear conflict of interest if evaluating research, whether the company's or others', in any peer review related to the company's in

Written byIrving Johnson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Krimsky goes on to claim that if a scientist feels compelled to join a board, he or she must agree "never to take any government- funded research projects that are directly related to any work in the company." In fact, some National Institutes of Health research is funded in small companies.

Krimsky's concerns seem embedded in the belief that once in contact with a commercial firm, all scientists become dishonest and incapable of any impartial action.

I believe it is precisely because of researchers' objectivity and ability to evaluate science in an increasingly complex and technologically driven world that their expertise not only is required on boards, but also is almost a necessity to protect the investment required to bring the benefits of discovery from the laboratory to the public. As with any other human endeavor, it is not a perfect world. Nobel laureates are sometimes used as "window dressing," ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies